CA2250704C - Recepteur de gdnf - Google Patents

Recepteur de gdnf Download PDF

Info

Publication number
CA2250704C
CA2250704C CA002250704A CA2250704A CA2250704C CA 2250704 C CA2250704 C CA 2250704C CA 002250704 A CA002250704 A CA 002250704A CA 2250704 A CA2250704 A CA 2250704A CA 2250704 C CA2250704 C CA 2250704C
Authority
CA
Canada
Prior art keywords
gdnfr
gdnf
protein
cells
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002250704A
Other languages
English (en)
Other versions
CA2250704A1 (fr
Inventor
Gary M. Fox
Shuqian Jing
Duanzhi Wen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA2250704A1 publication Critical patent/CA2250704A1/fr
Application granted granted Critical
Publication of CA2250704C publication Critical patent/CA2250704C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)

Abstract

La présente invention concerne le GDNF (facteur neurotrophique dérivé de lignées de cellules gliales), une neurotrophine puissante qui présente un large spectre d'activités biologiques sur divers types de cellules du système nerveux central et du système nerveux périphérique. Elle concerne aussi le clonage et la caractérisation d'un récepteur à haute affinité du GDNF. Cette molécule a été appelée récepteur de GDNF (GDNFR) étant donné qu'elle est le premier composant connu d'un système récepteur. Des séquences d'acides nucléiques et d'acides aminés des produits protéiques GDNFR sont décrites. Un domaine hydrophobe ayant les caractéristiques d'un peptide signal est situé à la terminaison amino, tandis qu'un second domaine hydrophobe au niveau de la terminaison carboxy est impliqué dans la liaison du récepteur avec la membrane cellulaire. L'absence de domaine transmembranaire et de région cytoplasmique indique que le GDNFR nécessite une ou plusieurs molécules accessoires pour transmettre les signaux à travers la membrane. L'ARNm de GDNFR est largement réparti à la fois dans les tissus du système nerveux et non neuraux, ce qui correspond à la répartition similaire trouvé pour le GDNF.
CA002250704A 1996-04-22 1997-04-15 Recepteur de gdnf Expired - Fee Related CA2250704C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US1590796P 1996-04-22 1996-04-22
US60/015,907 1996-04-22
US1722196P 1996-05-09 1996-05-09
US60/017,221 1996-05-09
US08/837,199 1997-04-14
US08/837,199 US6455277B1 (en) 1996-04-22 1997-04-14 Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
PCT/US1997/006281 WO1997040152A1 (fr) 1996-04-22 1997-04-15 Recepteur de gdnf

Publications (2)

Publication Number Publication Date
CA2250704A1 CA2250704A1 (fr) 1997-10-30
CA2250704C true CA2250704C (fr) 2005-04-12

Family

ID=27360445

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002250704A Expired - Fee Related CA2250704C (fr) 1996-04-22 1997-04-15 Recepteur de gdnf

Country Status (19)

Country Link
US (3) US6455277B1 (fr)
EP (1) EP0909316B1 (fr)
JP (1) JP2000509271A (fr)
KR (1) KR20000010571A (fr)
CN (1) CN1219967A (fr)
AT (1) ATE338115T1 (fr)
AU (1) AU720092B2 (fr)
BR (1) BR9708959A (fr)
CA (1) CA2250704C (fr)
CZ (1) CZ324598A3 (fr)
DE (1) DE69736597T2 (fr)
EA (1) EA002924B1 (fr)
ES (1) ES2271968T3 (fr)
HU (1) HUP9902640A3 (fr)
IL (1) IL126553A0 (fr)
NO (1) NO984757L (fr)
NZ (1) NZ332256A (fr)
SK (1) SK140398A3 (fr)
WO (1) WO1997040152A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) * 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
WO1997044356A2 (fr) * 1996-05-08 1997-11-27 Biogen, Inc. Test diagnostique de detection de la schizophrenie faisant appel a de la miacine
US6677135B1 (en) * 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
US20020068361A1 (en) * 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
AU7165998A (en) * 1997-05-30 1998-12-30 Amgen, Inc. Neurotrophic factor receptors
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
FI20000394A0 (fi) * 2000-02-21 2000-02-21 Airaksinen Matti GFRa4:n sukuisia tai siitä johdettuja aineita sekä niiden käyttö
WO2004085648A2 (fr) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Proteine de liaison de recepteur de nogo
CN1897977A (zh) * 2003-10-20 2007-01-17 Ns基因公司 帕金森氏病的体内基因治疗
AU2005258335B2 (en) 2004-06-24 2011-03-17 Biogen Ma Inc. Treatment of conditions involving demyelination
CA2583308C (fr) * 2004-10-08 2020-01-07 Georgia Tech Research Corporation Microencapsulation de cellules dans des hydrogels a l'aide de potentiels electrostatiques
SG163591A1 (en) 2005-07-08 2010-08-30 Biogen Idec Inc Sp35 antibodies and uses thereof
AU2006311828B2 (en) * 2005-11-04 2013-07-11 Biogen Ma Inc. Methods for promoting neurite outgrowth and survival of dopaminergic neurons
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
WO2013173364A2 (fr) 2012-05-14 2013-11-21 Biogen Idec Ma Inc. Antagonistes de lingo-2 pour le traitement d'affections impliquant des neurones moteurs
WO2016112270A1 (fr) 2015-01-08 2016-07-14 Biogen Ma Inc. Antagonistes de lingo-1 et leurs utilisations pour le traitement de troubles de démyélinisation
AU2017357931A1 (en) 2016-11-10 2019-06-20 Keros Therapeutics, Inc. GDNF fusion polypeptides and methods of use thereof
RU2690498C1 (ru) * 2018-05-17 2019-06-04 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" Способ получения ноотропной композиции на основе полипептидных комплексов, выделенных из нейронов и глиальных клеток, полученных методом направленной дифференцировки индуцированных плюрипотентных стволовых клеток человека
RU2732600C1 (ru) * 2019-12-26 2020-09-21 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях гипоксии, и способ ее получения
RU2752906C2 (ru) * 2019-12-26 2021-08-11 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях теплового шока, и способ ее получения

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
WO1990014363A1 (fr) 1989-05-19 1990-11-29 Amgen Inc. Inhibiteur de metalloproteinase
HU220795B1 (hu) 1991-09-20 2002-05-28 Amgen Inc. Gliasejtvonal-eredetű neurotróf faktorfehérjék, továbbá berendezések és gyógyászati készítmények idegsejtkárosodás megelőzésére és kezelésére
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods

Also Published As

Publication number Publication date
CA2250704A1 (fr) 1997-10-30
JP2000509271A (ja) 2000-07-25
ES2271968T3 (es) 2007-04-16
US6455277B1 (en) 2002-09-24
HUP9902640A2 (hu) 1999-11-29
IL126553A0 (en) 1999-08-17
SK140398A3 (en) 1999-04-13
BR9708959A (pt) 1999-08-03
CZ324598A3 (cs) 1999-01-13
AU720092B2 (en) 2000-05-25
NO984757D0 (no) 1998-10-12
EP0909316A1 (fr) 1999-04-21
NO984757L (no) 1998-12-21
US20030175876A1 (en) 2003-09-18
AU2730997A (en) 1997-11-12
EA199800933A1 (ru) 1999-04-29
EP0909316B1 (fr) 2006-08-30
DE69736597D1 (de) 2006-10-12
HUP9902640A3 (en) 2001-11-28
DE69736597T2 (de) 2006-12-21
CN1219967A (zh) 1999-06-16
NZ332256A (en) 2000-03-27
EA002924B1 (ru) 2002-10-31
ATE338115T1 (de) 2006-09-15
WO1997040152A1 (fr) 1997-10-30
KR20000010571A (ko) 2000-02-15
US20060166325A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
US20060166325A1 (en) Glial cell line-derived neurotrophic factor receptor
JP4909843B2 (ja) 截形グリア細胞系由来神経栄養因子
WO2000034475A9 (fr) Facteur de croissance neurotrophique issu des cellules gliales (grnf4), un facteur neurotrophique
CA2291608C (fr) Recepteurs du facteur neurotrope
US7138251B1 (en) Polynucleotides encoding a neurotrophic factor receptor
KR100399377B1 (ko) Ｇｄｎｆ 단백질의 분석방법 및 검정 기구
TW509696B (en) Glial cell line-derived neurotrophic factor receptor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170418